ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells

Cancer vaccines aim to induce CTL responses against tumors. Challenges for vaccine design are targeting Ag to dendritic cells (DCs) in vivo, facilitating cross-presentation, and conditioning the microenvironment for Th1 type immune responses. In this study, we report that ISCOM vaccines, which consist of ISCOMATRIX adjuvant and protein Ag, meet these challenges. Subcutaneous injection of an ISCOM vaccine in mice led to a substantial influx and activation of innate and adaptive immune effector cells in vaccine site-draining lymph nodes (VDLNs) as well as IFN-γ production by NK and NKT cells. Moreover, an ISCOM vaccine containing the model Ag OVA (OVA/ISCOM vaccine) was efficiently taken up by CD8α+ DCs in VDLNs and induced their maturation and IL-12 production. Adoptive transfer of transgenic OT-I T cells revealed highly efficient cross-presentation of the OVA/ISCOM vaccine in vivo, whereas cross-presentation of soluble OVA was poor even at a 100-fold higher concentration. Cross-presenting activity was restricted to CD8α+ DCs in VDLNs, whereas Langerin+ DCs and CD8α− DCs were dispensable. Remarkably, compared with other adjuvant systems, the OVA/ISCOM vaccine induced a high frequency of OVA-specific CTLs capable of tumor cell killing in different tumor models. Thus, ISCOM vaccines combine potent immune activation with Ag delivery to CD8α+ DCs in vivo for efficient induction of CTL responses.

[1]  S. Endres,et al.  An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma , 2011, International journal of cancer.

[2]  P. Stoitzner,et al.  Functional redundancy of Langerhans cells and Langerin+ dermal dendritic cells in contact hypersensitivity. , 2010, The Journal of investigative dermatology.

[3]  E. Maraskovsky,et al.  Presentation of tumour antigens by dendritic cells and challenges faced. , 2010, Current opinion in immunology.

[4]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[5]  S. Endres,et al.  ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II1 , 2009, The Journal of Immunology.

[6]  Franco Patrone,et al.  The use of dendritic cells in cancer immunotherapy. , 2008, Critical reviews in oncology/hematology.

[7]  N. Setterblad,et al.  Mycobacterium bovis BCG‐infected neutrophils and dendritic cells cooperate to induce specific T cell responses in humans and mice , 2008, European journal of immunology.

[8]  E. Maraskovsky,et al.  ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines , 2007, Expert review of vaccines.

[9]  Carl G. Figdor,et al.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting , 2007, Nature Reviews Immunology.

[10]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[11]  Kylie M. Price,et al.  Langerhans cells cross-present antigen derived from skin , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Carl Nathan,et al.  Neutrophils and immunity: challenges and opportunities , 2006, Nature Reviews Immunology.

[13]  J. Villadangos,et al.  Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. , 2005, Seminars in immunology.

[14]  A. Enk,et al.  Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. , 2005, Cancer research.

[15]  Clare L. Bennett,et al.  Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity , 2005, The Journal of cell biology.

[16]  T. Geijtenbeek,et al.  Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN , 2005, The Journal of experimental medicine.

[17]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[18]  S. Gordon,et al.  Ligand recognition by antigen-presenting cell C-type lectin receptors , 2004, Current Opinion in Immunology.

[19]  J. Harty,et al.  Neutrophil Involvement in Cross-Priming CD8+ T Cell Responses to Bacterial Antigens1 , 2004, The Journal of Immunology.

[20]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Luft,et al.  NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors , 2004, Clinical Cancer Research.

[22]  Franca Ronchese,et al.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. , 2004, Journal of immunological methods.

[23]  V. Cerundolo,et al.  Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.

[24]  G. Belz,et al.  Epidermal Viral Immunity Induced by CD8α+ Dendritic Cells But Not by Langerhans Cells , 2003, Science.

[25]  G. Belz,et al.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature. , 2003, Blood.

[26]  W. Oyen,et al.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. , 2003, Cancer research.

[27]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[28]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[29]  I. Mellman,et al.  Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Trinchieri,et al.  Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.

[31]  Nina Bhardwaj,et al.  Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[32]  S. Chen,et al.  A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. , 2001, Cancer research.

[33]  A. Sjölander,et al.  Induction of lymphocyte recruitment in the absence of a detectable immune response. , 2000, Vaccine.

[34]  C. Rooney,et al.  Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway1 , 2000, The Journal of Immunology.

[35]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[36]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[37]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.